What are the appropriate indications, dosing regimens, contraindications, and alternative therapies for azithromycin?

Azithromycin: Indications, Dosing, Contraindications, and Alternatives

Primary Indications and Dosing

Azithromycin is a first-line antibiotic for chlamydial infections and atypical respiratory pathogens, with specific dosing regimens that vary by indication and patient age.

Chlamydial Infections in Adolescents and Adults

• Recommended regimen: Azithromycin 1 g orally as a single dose 1
• Alternative: Doxycycline 100 mg orally twice daily for 7 days 1
• Azithromycin and doxycycline demonstrate equal efficacy for uncomplicated genital chlamydia 1
• Azithromycin should be prioritized when patient compliance is questionable, as single-dose directly observed therapy is more cost-effective in populations with erratic healthcare-seeking behavior 1
• The WHO recommends azithromycin only if doxycycline has failed, is contraindicated, or if major adherence concerns exist, given recent evidence of decreased azithromycin efficacy and FDA safety warnings 1

Chlamydial Infections in Children

Age-based dosing is critical:

• Children weighing <45 kg: Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses for 14 days 1
• Children weighing ≥45 kg but <8 years: Azithromycin 1 g orally as a single dose 1
• Children ≥8 years: Azithromycin 1 g orally single dose OR doxycycline 100 mg orally twice daily for 7 days 1

Gonococcal Infections (Dual Therapy)

• Patients with gonococcal infection require presumptive treatment for chlamydia due to high coinfection rates (10-30%) 1
• Ceftriaxone 250 mg IM single dose PLUS azithromycin 1 g orally single dose 1
• This dual therapy approach has contributed to substantial decreases in chlamydial prevalence 1

Respiratory Tract Infections

Community-Acquired Pneumonia (Pediatric):

• Preferred for atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae): 1
  • IV: 10 mg/kg on days 1-2, then transition to oral
  • Oral: 10 mg/kg on day 1, followed by 5 mg/kg/day once daily on days 2-5
• Alternative: Clarithromycin 15 mg/kg/day in 2 doses or erythromycin 40 mg/kg/day in 4 doses 1
• For children >7 years: Doxycycline 2-4 mg/kg/day in 2 doses 1

Pertussis Treatment and Prophylaxis:

• Infants <6 months: 10 mg/kg per day for 5 days 1
• Infants and children ≥6 months: 10 mg/kg (maximum 500 mg) on day 1, followed by 5 mg/kg per day (maximum 250 mg) on days 2-5 1
• Adults: 500 mg on day 1, followed by 250 mg per day on days 2-5 1
• Azithromycin is preferred over erythromycin for infants <1 month due to lower risk of infantile hypertrophic pyloric stenosis (IHPS) 1

Acute Sinusitis:

• Evidence shows antibiotics provide modest benefit over placebo, with faster resolution of purulent secretions but increased adverse effects 1
• Azithromycin is less effective than amoxicillin-clavulanic acid for maxillary sinusitis 1

Streptococcal Pharyngitis/Tonsillitis

• Azithromycin 12 mg/kg/day for 5 days (total dose 60 mg/kg) provides optimal GABHS eradication in children 2
• Alternative regimen: 20 mg/kg once daily for 3 days 2
• Azithromycin results in more recurrences than phenoxymethylpenicillin, which remains first-line therapy 3, 2
• Use azithromycin for penicillin hypersensitivity, suspected nonadherence to 10-day penicillin regimen, or beta-lactam treatment failure 2

Conjunctivitis

Chlamydial Conjunctivitis:

• Adults: Azithromycin 1 g orally single dose OR doxycycline 100 mg orally twice daily for 7 days 1
• Children ≥8 years: Same as adults 1
• Children <8 years but ≥45 kg: Azithromycin 1 g orally single dose 1
• Neonates: Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses for 14 days 1

Pharmacokinetics and Clinical Considerations

Azithromycin demonstrates unique pharmacokinetic properties that enable convenient dosing:

• Absolute bioavailability: 38% 4
• Terminal elimination half-life: 68-72 hours 4
• Tissue concentrations exceed serum levels by >100-fold in lung, tonsil, and other tissues 4
• Extensive intracellular accumulation in phagocytes (>1000-fold greater than serum) 4
• Food increases Cmax by 23-56% but does not affect AUC 4

Contraindications and Safety

Absolute Contraindications:

• Hypersensitivity to azithromycin or any macrolide agent 1
• QTc >450 ms for men or >470 ms for women 1
• Concurrent use with astemizole, cisapride, pimazole, or terfenadine 1

Relative Contraindications and Precautions:

• Impaired hepatic function requires cautious prescribing 1
• Baseline ECG and liver function tests should be obtained before initiating therapy 1
• Repeat ECG at 1 month to check for new QTc prolongation; discontinue if present 1
• Monitor liver function tests at 1 month, then every 6 months during long-term therapy 1

Adverse Effects:

• Most common: Gastrointestinal symptoms (diarrhea 3.6%, abdominal pain 2.5%) 5
• Azithromycin is better tolerated than erythromycin, with fewer and less severe GI side effects 6, 3, 5
• Overall side effect rate: 12.0% (significantly less than comparator antibiotics at 14.2%) 5
• Only 0.7% of patients withdraw from treatment (vs. 2.6% with comparators) 5
• Transient ALT/AST elevations in 1.5-1.7% of patients 5
• Risk of IHPS in neonates <1 month with erythromycin (not reported with azithromycin) 1

Drug Interactions:

• No significant interactions with theophylline, warfarin, cimetidine, carbamazepine, or methylprednisolone 4
• Avoid concurrent aluminum- or magnesium-containing antacids (reduces absorption rate) 1
• Nelfinavir significantly increases azithromycin Cmax and AUC (2.36-fold and 2.12-fold, respectively) 4

Antimicrobial Resistance Concerns

Emerging resistance patterns require judicious use:

• Macrolide resistance genes (erm(C) and msr(A)) increase with azithromycin exposure, particularly in stool samples (0% baseline to 69% at day 14) 7
• Azithromycin efficacy for genital Mycoplasma genitalium decreased from 85.3% before 2009 to 67.0% since 2009 1
• Ribosomal modification at positions A2058 and A2059 confers cross-resistance to macrolides, lincosamides, and streptogramins B 4
• Microbiological screening before and during therapy is recommended when patients can expectorate sputum 1

Alternative Therapies

For Chlamydial Infections:

• First alternative: Doxycycline 100 mg orally twice daily for 7 days 1
• Second-line alternatives: 1
  • Erythromycin base 500 mg orally four times daily for 7 days
  • Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
  • Ofloxacin 300 mg orally twice daily for 7 days
  • Levofloxacin 500 mg orally once daily for 7 days
• Erythromycin is less efficacious than azithromycin or doxycycline, with frequent GI side effects that discourage compliance 1

For Respiratory Tract Infections:

• Amoxicillin-clavulanic acid demonstrates equivalent efficacy to azithromycin for otitis media and community-acquired pneumonia 8, 3
• Cefaclor, clarithromycin, and erythromycin are alternatives, though symptoms resolve more rapidly with azithromycin 8
• For GABHS pharyngitis: Phenoxymethylpenicillin (penicillin V) remains the gold standard 3, 2

For Pertussis:

• Clarithromycin: Not specified for infants <1 month; for older children, dosing not detailed in guidelines 1
• Erythromycin 40-50 mg/kg/day in 4 divided doses for 14 days (not preferred for infants <1 month due to IHPS risk) 1

Special Populations

Pregnancy:

• FDA Pregnancy Category B 1
• Erythromycin or amoxicillin recommended for chlamydia during pregnancy (not doxycycline, quinolones, or tetracyclines) 1

Neonates:

• For infants <1 month with pertussis: Azithromycin is preferred over erythromycin due to IHPS risk 1
• Monitor all neonates receiving macrolides for IHPS and other serious adverse events 1

Renal Insufficiency:

• Mild to moderate impairment (GFR 10-80 mL/min): Minimal effect (5.1% increase in Cmax, 4.2% increase in AUC) 4
• Severe impairment (GFR <10 mL/min): 61% increase in Cmax, 35% increase in AUC 4
• No specific dosage adjustment recommended, but caution advised 4

Geriatric Patients:

• Elderly women show 30-50% higher peak concentrations, but no significant accumulation occurs 4
• No dosage adjustment required based on age 4

Follow-Up and Monitoring

Post-Treatment Assessment:

• Patients treated with azithromycin or doxycycline do not require retesting unless symptoms persist or reinfection is suspected 1
• Test of cure may be considered 3 weeks after erythromycin completion 1
• Retesting at approximately 3 months is recommended for all patients with chlamydial or gonococcal infection to detect reinfection 1
• Patients should abstain from sexual intercourse for 7 days after single-dose therapy or until completion of 7-day regimen 1
• All sex partners must be treated before resuming sexual activity 1

Long-Term Macrolide Therapy:

• For chronic respiratory conditions, assess efficacy at 6 and 12 months 1
• Discontinue if no benefit is demonstrated 1
• Consider stopping treatment periodically each year, even if beneficial 1

Clinical Pitfalls to Avoid

• Do not use azithromycin monotherapy if nontuberculous mycobacteria are identified 1
• Avoid macrolide testing for 2 weeks before microbiological evaluation for NTM 1
• Low serum concentrations may allow breakthrough bacteremia in severely ill patients, though tissue concentrations are more clinically relevant 6
• Sexual abuse must be considered in preadolescent children with chlamydial infection 1
• Nonculture tests (EIA, DFA) should not be used in children due to false-positive results from cross-reaction with C. pneumoniae and fecal flora 1
• Dispensing medications on-site with directly observed first dose maximizes compliance 1